Skip to main content
SpringerLink
Log in

New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Although highly effective, warfarin use is complicated by its unpredictable narrow therapeutic window, genetic heterogeneity in pharmacokinetic response, numerous food and drug interactions, and the need for regular international normalized ratio (INR) monitoring. Currently, several novel oral anticoagulant (NOAC) drugs (dabigatran, rivaroxaban, apixaban) are available on the market as alternatives to warfarin. These agents all feature more predictable pharmacodynamic and pharmacokinetic properties than warfarin. Additionally, the NOACs do not require routine monitoring of coagulation parameters, and have a relatively lower potential for interactions with drug, herb, and dietary constituents, which enhances the convenience of management for both patients and health professionals alike. However, there are other considerations regarding the use of NOACs that must be taken into account during management of therapy. In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation. The more frequent dosing needed for NOACs may reduce adherence, especially in elderly patients with polypharmacy. Furthermore, NOACs, especially dabigatran, are not as well tolerated as warfarin in patients with gastrointestinal diseases. Overall, the availability of the NOACs has expanded the treatment armamentarium, but they are not without risk. Given the limited experience with the NOACs, their limited range of indications, and their cost, the characteristics of each anticoagulant must be carefully considered to carefully select the agent that will provide the optimal risk/benefit profile in the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186:175–80.

    PubMed  Google Scholar 

  2. Bristol-Myers Squibb Company. Coumadin (warfarin sodium) highlights of prescribing information. 2011. http://packageinsertsbmscom/pi/pi_coumadinpdf. Accessed 11 April 2013.

  3. Australian government Department of Health and Ageing. Review of anticoagulation therapies in atrial fibrillation. 2012. http://wwwpbsgovau/reviews/atrial-fibrillation-files/issues-and-options-paperpdf. Accessed 29 April 2013.

  4. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation clinical perspective. Circulation. 2011;123:2562–70.

    Article  PubMed  Google Scholar 

  5. Aspen Pharma. Coumadin (warfarin sodium) product information. 2010. http://wwwaspenpharmacomau/product_info/pi/PI_Coumadinpdf. Accessed 11 April 2013.

  6. Bayer Australia. Xarelto (rivaroxaban) product information. 2012. http://wwwbayerresourcescomau/resources/uploads/PI/file9466pdf. Accessed 11 April 2013.

  7. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S–16S.

    Article  CAS  PubMed  Google Scholar 

  8. Boeringer Ingelheim. Pradaxa (dabigatran etexilate) product information. 2012. http://wwwpbsgovau/reviews/atrial-fibrillation-files/14a-boehringer-ingelheim-appendicespublicpdf. Accessed 11 April 2013.

  9. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5:433–51.

    Article  CAS  PubMed  Google Scholar 

  10. Bristol-Myers Squibb. Eliquis (apixaban) product information. 2012. http://securehealthlinksnetau/content/bms/picfm?product=bqpeliqu11112. Accessed 11 April 2013.

  11. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32:165–72.

    Article  CAS  PubMed  Google Scholar 

  12. Beatty SJ, Mehta BH, Rodis JL. Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother. 2005;39:744–7.

    Article  PubMed  Google Scholar 

  13. Fagan TC, Oexmann MJ. Effects of high protein, high carbohydrate, and high fat diets on laboratory parameters. J Am Coll Nutr. 1987;6:333–43.

    Article  CAS  PubMed  Google Scholar 

  14. Dang M-TN, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008–12.

    Article  CAS  PubMed  Google Scholar 

  15. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049–56.

    Article  CAS  PubMed  Google Scholar 

  16. Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo). 2012;10:110–5.

    Article  Google Scholar 

  17. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.

    Article  CAS  PubMed  Google Scholar 

  18. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–95.

    Article  CAS  PubMed  Google Scholar 

  19. Nutescu EA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70(Suppl 1):S3–11.

    Article  CAS  PubMed  Google Scholar 

  20. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59.

    Article  CAS  PubMed  Google Scholar 

  21. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453–61.

    CAS  PubMed  Google Scholar 

  22. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242–7.

    Article  CAS  PubMed  Google Scholar 

  23. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–80.

    Article  CAS  PubMed  Google Scholar 

  24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  25. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.

    Article  CAS  PubMed  Google Scholar 

  26. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673–80.

    Article  CAS  PubMed  Google Scholar 

  27. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436–41.

    Article  CAS  PubMed  Google Scholar 

  28. Moyer TP, O’Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404–12.

    Article  CAS  PubMed  Google Scholar 

  30. Bristol-Myers Squibb. Eliquis (apixaban) prescription information. 2012. http://wwwaccessdatafdagov/drugsatfda_docs/label/2012/202155s000lblpdf. Accessed 11 April 2013.

  31. Pharmaceuticals J. Xarelto (rivaroxaban) highlights of prescribing information. 2011. http://wwwaccessdatafdagov/drugsatfda_docs/label/2011/202439s001lblpdf. Accessed 11 April 2013.

  32. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement—a systematic review and meta analysis. Thromb Res. 2010;125:e159–66.

    Article  CAS  PubMed  Google Scholar 

  33. Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009;66:123–33.

    Article  CAS  PubMed  Google Scholar 

  34. Monagle P, Chalmers E, Chan A, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):887S–968S.

    Article  CAS  PubMed  Google Scholar 

  35. Bristol-Myers Squibb Company. Highlights of prescribing information, Coumadin. 2011. http://wwwaccessdatafdagov/drugsatfda_docs/label/2011/009218s107lblpdf. Accessed 29 Nov 2013.

  36. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–736S.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception. 2011;84:128–32.

    Article  CAS  PubMed  Google Scholar 

  38. Peake LJ, Grover SR, Monagle PT, Kennedy AD. Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin. J Paediatr Child Health. 2011;47:893–7.

    Article  PubMed  Google Scholar 

  39. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med. 2006;22:17–32.

    Article  PubMed  Google Scholar 

  40. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326–43.

    Article  CAS  PubMed  Google Scholar 

  41. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S.

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54:349–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001;4:176–84.

    CAS  PubMed  Google Scholar 

  44. Duthie GG, Kyle JA, Jenkinson AM, Duthie SJ, Baxter GJ, Paterson JR. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. J Agric Food Chem. 2005;53:2897–900.

    Article  CAS  PubMed  Google Scholar 

  45. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther. 2006;79:125–33.

    Article  CAS  PubMed  Google Scholar 

  46. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38:50–2.

    Article  PubMed  Google Scholar 

  47. Daugherty NE, Smith KM. Dietary supplement and selected food interactions with warfarin. Pharmacol Update. 2006;29:309–14.

    Google Scholar 

  48. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453–60.

    Article  CAS  PubMed  Google Scholar 

  49. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase the risk of gastrointestinal bleeding—a systematic review and meta-analysis. Ned Tijdschr Geneeskd. 2013;1(45):105–12.

    Google Scholar 

  50. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  51. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11(246–52):e1–5.

    Google Scholar 

  52. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA. 2001;285:2864–70.

    Article  CAS  PubMed  Google Scholar 

  53. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.

    Article  PubMed  Google Scholar 

  54. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.

    Article  PubMed  Google Scholar 

  55. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.

    Article  PubMed  Google Scholar 

  56. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.

    Article  PubMed  Google Scholar 

  57. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S–226S.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–77S.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–94S.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Kuijer PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457.

    Article  CAS  PubMed  Google Scholar 

  62. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.

    PubMed  Google Scholar 

  63. Harenberg J, Giese C, Marx S, Kramer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2012;38:16–22.

    Article  CAS  PubMed  Google Scholar 

  64. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.

    Article  PubMed  Google Scholar 

  65. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013. [Epub ahead of print].

  66. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–43.

    Article  CAS  PubMed  Google Scholar 

  67. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2013;111. [Epub ahead of print].

  68. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;3. doi:10.1002/14651858.

  69. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016–23.

    Article  CAS  PubMed  Google Scholar 

  71. UW Medicine. Spontaneous intraparenchymal hemorrhage reversal guide for target specific oral anticoagulants. http://deptswashingtonedu/anticoag/home/sites/default/files/IPH_DabigatranRivaroxabanApixaban_reversal_0pdf. Accessed 6 Aug 2013.

  72. Brent Reed AM. UNC health care guideline management of dabigatran in adults. 2011. http://emcritorg/wp-content/uploads/dabigatran-unc-guideline3pdf. Accessed 28 Aug 2013.

  73. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S–50S.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood. 2012;120:4699–705.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Vílchez JA, Gallego P, Lip GY. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf. 2013;. doi:10.1177/2042098613507945.

    Google Scholar 

  76. Pototski M, Amenabar JM. Dental management of patients receiving anticoagulation or antiplatelet treatment. J Oral Sci. 2007;49:253–8.

    Article  CAS  PubMed  Google Scholar 

  77. Alaali Y, Barnes GD, Froehlich JB, Kaatz S. Management of oral anticoagulation in patients undergoing minor dental procedures. J Mich Dent Assoc. 2012;94:36–41.

    PubMed  Google Scholar 

  78. Cushman M, Lim W, Zakai NA. 2011 clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. 2011. http://wwwhematologyorg/Practice/Guidelines/2934aspx. Accessed 17 July 2013.

  79. Food and Drug Administration (FDA). FDA pregnancy categories. 2008. http://wwwgpogov/fdsys/pkg/FR-2008-05-29/pdf/E8-11806pdf. Accessed 18 Dec 2013.

  80. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.

    Article  CAS  PubMed  Google Scholar 

  81. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.

    Article  CAS  PubMed  Google Scholar 

  82. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013;61:1853–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No external funding was used in the preparation of this review. None of the authors have any potential conflicts of interest affecting the content of this review.

Author information

Authors and Affiliations

  1. Graduate School of Health: School of Pharmacy, University of Technology Sydney (UTS), CB01.13, PO Box 123, Broadway, NSW, 2007, Australia

    Yishen Wang & Beata Bajorek

Authors
  1. Yishen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beata Bajorek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yishen Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Y., Bajorek, B. New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations. Am J Cardiovasc Drugs 14, 175–189 (2014). https://doi.org/10.1007/s40256-013-0061-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-013-0061-0

Keywords

Search

Navigation